T Cell Infusion
Showing 1 - 25 of >10,000
Hematologic Malignancy Trial in Bologna
Recruiting
- Hematologic Malignancy
-
Bologna, ItalyProgramma Dipartimentale Terapie Cellulari Avanzate
Apr 17, 2023
Recurrent DLBCL, Refractory DLBCL Trial in Duarte (procedure, biological, radiation)
Not yet recruiting
- Recurrent Diffuse Large B-Cell Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma
- Biospecimen Collection
- +6 more
-
Duarte, CaliforniaCity of Hope Medical Center
Mar 24, 2023
Brain Tumor Trial in Washington (TAA-T)
Recruiting
- Brain Tumor
- TAA-T
-
Washington, District of ColumbiaBrain Tumor Institute, Children's National Medical Center
Aug 30, 2022
B-cell Lymphoma Trial in Xuzhou (ASCT+CAR-T Cell Infusion)
Recruiting
- B-cell Lymphoma
- ASCT+CAR-T Cell Infusion
-
Xuzhou, Jiangsu, ChinaThe Affiliated Hospital of Xuzhou Medical University
Feb 23, 2023
Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia Trial in Westwood (EAGD T-cell infusion (Phase
Recruiting
- Acute Myeloid Leukemia
- +3 more
- EAGD T-cell infusion (Phase I)
- EAGD T-cell infusion (Expansion)
-
Westwood, KansasUniversity of Kansas Cancer Center
Mar 15, 2022
Systemic Lupus Erythematosus Trial (CD19 CAR-T cell infusion)
Not yet recruiting
- Systemic Lupus Erythematosus
- CD19 CAR-T cell infusion
- (no location specified)
Oct 24, 2023
Hepatocellular Carcinoma Trial in Guangzhou (TCR-T, No intervention and TCR-T (at crossover))
Completed
- Hepatocellular Carcinoma
- TCR-T
- No intervention and TCR-T (at crossover)
-
Guangzhou, Guangdong, ChinaThe First Affiliated Hospital, Sun-Yat Sen University
Jun 27, 2022
B-Cell Leukemia, B-Cell Lymphoma, B-cell Tumors Trial in Kunming (Anti-CD19 Autologous CAR-T Cell Infusion)
Recruiting
- B-Cell Leukemia
- +2 more
- Anti-CD19 Autologous CAR-T Cell Infusion
-
Kunming, Yunnan, China920th Hospital of Joint Logistics Support Force of People's Libe
Jul 9, 2023
Using IMC to Analyze the Impact of ICANS on Microglia
Recruiting
- ICANS, Grade Unspecified
- CAR T-Cell-Related Encephalopathy Syndrome
- There will be no intervention as we will study patients that undergo autopsy after CAR T cell infusion.
-
Freiburg, Baden Württemberg, GermanyFreiburg University Medical Center
Apr 12, 2023
Acute T-lymphoblastic Leukemia, Acute T-lymphoblastic Lymphoma Trial in Xuzhou (CAR-T Cell Infusion)
Recruiting
- Acute T-lymphoblastic Leukemia
- Acute T-lymphoblastic Lymphoma
- CAR-T Cell Infusion
-
Xuzhou, Jiangsu, ChinaThe Affiliated Hospital of Xuzhou Medical University
Feb 23, 2023
Hematopoietic Organs; Disorder Trial in Hong Kong (CD62L depleted donor lymphocyte infusion)
Recruiting
- Hematopoietic Organs; Disorder
- CD62L depleted donor lymphocyte infusion
-
Hong Kong, Hong KongHong Kong Children's Hospital
Sep 6, 2023
Malignant Tumor, Metastatic Malignant Tumor in the Brain, Metastatic Malignant Tumor in the Leptomeninges Trial in Duarte
Recruiting
- Malignant Neoplasm
- +4 more
- Chimeric Antigen Receptor T-Cell Therapy
-
Duarte, CaliforniaCity of Hope Medical Center
Sep 14, 2022
NSCLC, Gastric Cancer, Hepatocellular Carcinoma Trial in Beijing, Shanghai (natural killer T cell)
Recruiting
- Non-small Cell Lung Cancer
- +3 more
- natural killer T cell
-
Beijing, China
- +1 more
Apr 26, 2022
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, MDS Trial in Beijing (Ex-vivo expanded ?d T cell infusion)
Recruiting
- Acute Myeloid Leukemia
- +3 more
- Ex-vivo expanded γδ T cell infusion
-
Beijing, ChinaChinese PLA General Hospital
Mar 24, 2022
Hematologic Malignancy Trial in Pavia, Rome, Turin (BPX-501 T cells, rimiducid)
Active, not recruiting
- Hematologic Malignancy
- BPX-501 T cells
- rimiducid
-
Pavia, Italy
- +2 more
Jul 10, 2022
Chronic GVHD, Hematologic and Lymphocytic Disorder, Steroid Refractory GVHD Trial in Duarte (procedure, biological, other)
Not yet recruiting
- Chronic Graft Versus Host Disease
- +2 more
- Biopsy
- +11 more
-
Duarte, CaliforniaCity of Hope Medical Center
Aug 7, 2023
Leukemia, Lymphoma, Lymphoma, B-Cell Trial in New York (CAR T-Cell Infusion)
Withdrawn
- Leukemia
- +2 more
- CAR T-Cell Infusion
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Mar 4, 2022
Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory
Active, not recruiting
- Peripheral T Cell Lymphoma
- Pediatric Hodgkin Lymphoma
- Brentuximab Vedotin (Genetical Recombination)
-
Tokyo, JapanTakeda Selected Site
Oct 11, 2022
Pediatric Solid Tumor, Osteosarcoma, Rhabdomyosarcoma Trial in Memphis (Fludarabine, Cyclophosphamide, MESNA)
Recruiting
- Pediatric Solid Tumor
- +15 more
- Fludarabine
- +3 more
-
Memphis, TennesseeSt. Jude Children's Research Hospital
Jun 30, 2022
Non-hodgkin Lymphoma,B Cell, Multiple Myeloma, Acute Lymphoblastic Leukemia, Adult Trial in Atlanta (Fludarabine,
Not yet recruiting
- Non-hodgkin Lymphoma,B Cell
- +2 more
-
Atlanta, GeorgiaCaitlin Guzowski
Jun 9, 2023
COL6A3 Positive, HLA-A*0201 Positive Cells Present, PRAME Positive Trial in Houston (biological, drug, procedure)
Active, not recruiting
- COL6A3 Positive
- +3 more
- Aldesleukin
- +4 more
-
Houston, TexasM D Anderson Cancer Center
Sep 22, 2022
Lymphoma Trial in Seattle (biological, other, procedure)
Not yet recruiting
- Lymphoma
- Immune Globulin Infusion (Human), 10% Solution
- +5 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jul 21, 2023
Carcinoma Trial (Intravenous infusion anti-CEA-CAR-T cell)
Not yet recruiting
- Carcinoma
- Intravenous infusion anti-CEA-CAR-T cell
- (no location specified)
Aug 22, 2023
Adult Grade III Lymphomatoid Granulomatosis, Cutaneous B-cell Non-Hodgkin Lymphoma, MALT Trial in Duarte (biological, procedure,
Active, not recruiting
- Adult Grade III Lymphomatoid Granulomatosis
- +23 more
- autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells
- +2 more
-
Duarte, CaliforniaCity of Hope Medical Center
Jan 4, 2023
Stage IIIB(N2) NSCLC, Stage IIA NSCLC, Stage IIB NSCLC Trial in Beijing (Pembrolizumab 200 mg IV infusion)
Not yet recruiting
- Stage IIIB(N2) Non-small Cell Lung Cancer
- +3 more
- Pembrolizumab 200 mg IV infusion
-
Beijing, Beijing, ChinaPeking University
May 30, 2023